Table 3 Sensitivity, specificity and balanced accuracy of individual markers to predict a lower GI tumor in the test and expansion cohorts using different cut-offs

From: A combination of the immunohistochemical markers CK7 and SATB2 is highly sensitive and specific for distinguishing primary ovarian mucinous tumors from colorectal and appendiceal metastases

Test cohort

Binary criteria (absent versus present)

Sensitivity

95% CI

Specificity

95% CI

Accuracy

95% CI

SATB2 present

0.90

0.85

0.94

0.87

0.81

0.92

0.89

0.85

0.92

CK7 absent

0.81

0.75

0.86

0.97

0.94

0.99

0.88

0.84

0.91

PAX8 absent

0.97

0.94

0.99

0.45

0.37

0.53

0.76

0.72

0.81

CDX2 present

0.98

0.96

1.00

0.30

0.23

0.38

0.71

0.66

0.75

CK20 present

0.87

0.82

0.91

0.18

0.12

0.25

0.59

0.54

0.64

Binary criteria (diffuse versus non-diffuse)

  CK7 nondiffuse

0.92

0.88

0.95

0.91

0.85

0.95

0.92

0.88

0.94

  SATB2 diffuse

0.80

0.74

0.85

0.94

0.86

0.97

0.86

0.82

0.89

  CDX2 diffuse

0.81

0.76

0.86

0.83

0.75

0.89

0.82

0.78

0.86

  PAX8 nondiffuse

0.97

0.94

0.99

0.12

0.07

0.18

0.63

0.58

0.68

  CK20 diffuse

0.71

0.64

0.77

0.56

0.48

0.64

0.65

0.60

0.70

Expansion cohort

Binary criteria (absent versus present)

  SATB2 present

0.95

0.91

0.97

0.88

0.83

0.92

0.92

0.88

0.94

  PAX8 absent

0.97

0.94

0.99

0.41

0.35

0.49

0.71

0.67

0.75

Binary criteria (diffuse versus non-diffuse)

  SATB2 diffuse

0.80

0.74

0.85

0.94

0.89

0.97

0.96

0.83

0.90

  PAX8 nondiffuse

0.97

0.94

0.99

0.14

0.09

0.19

0.58

0.53

0.63